Autoimmune treatment market seen reaching $16.53 billion by 2030

The Business Research Company says the autoimmune treatment market will rise from $8.63 billion in 2025 to $9.84 billion in 2026, then climb to $16.53 billion by 2030. The report points to higher diagnosis rates, more biologics, and growing healthcare spending as key drivers, with North America leading the market in 2025.

Why it matters: - Autoimmune treatment is becoming a larger healthcare market as diagnosis rates rise and more patients seek long-term disease management. - The forecast signals stronger demand for specialty drugs, biologics, and patient-monitoring tools over the next several years. - Healthcare systems are expected to face growing pressure to fund advanced therapies and follow-up care for chronic autoimmune conditions.

What happened: - The Business Research Company published its Autoimmune Treatment Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035. - The report says the autoimmune treatment market will grow from $8.63 billion in 2025 to $9.84 billion in 2026. - The report projects the market will reach $16.53 billion by 2030. - The report places North America as the largest regional market in 2025.

The details: - The report says the market grew on better availability of immunosuppressive medications, broader rheumatology and immunology services, improved clinical expertise, higher diagnosis rates and wider access to specialty drugs. - The report expects continued growth from investments in new biologic drugs, demand for personalized treatment, broader use of digital monitoring tools, and more emphasis on reducing long-term complications. - The report highlights biologics, targeted immunomodulators, long-term management programs, individualized therapy regimens and combination drug treatments as major trends. - Autoimmune treatment is designed to regulate or suppress an immune response that attacks healthy cells. - The goal is to control symptoms and improve quality of life for patients with autoimmune disorders. - The report says global healthcare spending is a major growth driver for the market. - The UK Office for Budget Responsibility and the UK Treasury project health expenditure will rise to £192 billion ($244.43 billion) in 2024/25 from £182 billion ($231.70 billion) in 2022/23. - KFF’s National Health Expenditures Accounts project U.S. health spending will increase 5% between 2023 and 2024 to $4.9 trillion. - The report covers North America, Asia-Pacific, South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa. - The report says North America leads because of advanced healthcare infrastructure, high diagnosis rates and broad access to specialty treatments.

Between the lines: - The forecast points to a market moving from basic symptom control toward more tailored and technology-supported care. - The emphasis on biologics and targeted treatments suggests continued pressure on drug developers to differentiate products in a crowded specialty market. - The regional breakdown implies that access to care will remain a key divider between mature markets and faster-growing emerging regions.

What's next: - The Business Research Company says its 2026 reports include market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, and updated graphics and tables. - The company is also directing readers to its sample report and full market report.